BioCryst Pharmaceuticals is recruiting for a first-in-human study of its novel oral therapy for PNH!
BCX9930 is a novel, oral Factor D inhibitor currently in Phase 1 clinical development for the treatment of complement-mediated diseases, including PNH. This three-part study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCX9930 with single and multiple ascending doses.
BioCryst Pharmaceuticals is currently recruiting both healthy subjects and those with PNH to enroll in the 148-participant study. Clinical trial sites for this study are currently located in South Africa.
For more information on this clinical trial, visit ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04330534…
For more information about BioCryst Pharmaceuticals’ Complement Program visit: https://www.biocryst.com/our-program/complement-program/
